The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis
- 1 November 2004
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 3 (6) , 525-534
- https://doi.org/10.1517/14740338.3.6.525
Abstract
Riluzole is the only disease-modifying drug approved for the treatment of amyotrophic lateral sclerosis (ALS), in which it has been demonstrated to extend survival. The overall tolerability of rilu...Keywords
This publication has 25 references indexed in Scilit:
- UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALSAnnual Review of Neuroscience, 2004
- Riluzole-induced neutropeniaNeurology, 2004
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004
- Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2002
- Long-term safety of riluzole in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2002
- A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2001
- Methemoglobinemia Due to RiluzoleNew England Journal of Medicine, 2000
- A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosisAnnals of Neurology, 1996
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993